MiNA Therapeutics
MiNA Therapeutics is a clinical-stage biopharmaceutical company developing small activating RNA (RNAa) therapeutics, a novel class of oligonucleotide medicines that restore gene function. It serves pharmaceutical partners through research collaborations and licensing agreements, with lead asset MTL-CEBPA in Phase 2 development for liver cancer.
- Company typePrivate
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MiNA Therapeutics does
MiNA Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 and headquartered at Imperial College London's White City Campus in London, UK. The company develops small activating RNA (RNAa) therapeutics, an entirely new class of oligonucleotide medicines that restore or boost normal gene and protein function by recruiting endogenous transcriptional complexes to target genes. Its proprietary platform combines a bioinformatics discovery engine for saRNA sequence design with exclusively in-licensed SMARTICLES liposomal delivery technology, enabling advancement of new RNAa candidates from concept to clinical trial in approximately two years. The pipeline includes MTL-CEBPA (the first RNAa medicine in clinical development, evaluated in over 130 patients with advanced liver cancer and solid tumors), MTL-HBG (a preclinical in vivo therapy for sickle cell disease), and MTL-STING (a second oncology candidate).
MiNA generates revenue through research collaborations, option-to-license agreements, and milestone/royalty arrangements with major pharmaceutical partners including Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku. These partnerships span oncology, metabolic diseases, neurological disorders, and rare genetic diseases. The company has raised over $100M cumulatively across multiple funding rounds including a £23M Series A led by aMoon in 2020 and a $15M direct equity investment from Eli Lilly in 2021. Go-to-market is exclusively enterprise partnership-based — MiNA does not commercialize directly, relying on pharmaceutical partners for late-stage development and commercialization.
MiNA Therapeutics firmographics
Firmographics- Name
- MiNA Therapeutics
- Legal name
- MiNA Therapeutics Limited
- Website
- https://minatx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MiNA Therapeutics is a clinical-stage biopharmaceutical company developing small activating RNA (RNAa) therapeutics, a novel class of oligonucleotide medicines that restore gene function. It serves pharmaceutical partners through research collaborations and licensing agreements, with lead asset MTL-CEBPA in Phase 2 development for liver cancer.
- Ownership category
- akta.pro rank
MiNA Therapeutics industry classification
Industry- Product category
- RNA-based Therapeutics (saRNA / RNAa)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)
Keywords
Where MiNA Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
MiNA Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Research Collaborations and Licensing: MiNA generates revenue through strategic research collaborations with pharmaceutical companies where partners provide funding for research activities, upfront payments, and milestone payments tied to development achievements. Examples include collaborations with Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku.
- Development Milestones and Royalties: Collaborations typically include option fees, milestone payments upon achieving clinical and regulatory milestones, and potential royalty payments on net sales of any approved products developed through the partnership.
- Equity Investment: The company has raised significant equity financing including Series A funding and direct investments from pharmaceutical partners like Lilly's $15m equity investment and Sosei's £35m strategic investment.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
MiNA Therapeutics product offering
Product offeringCore offering
MiNA Therapeutics develops a proprietary pipeline of small activating RNA (RNAa) therapeutics — an entirely new class of oligonucleotide medicines that restore or boost normal gene expression at the transcriptional level. Its clinical-stage assets include MTL-CEBPA (cancer immunotherapy combination), MTL-HBG (sickle cell disease) and MTL-STING (cancer immunotherapy), supported by an in-house bioinformatics discovery engine and the in-licensed SMARTICLES liposomal delivery platform. MiNA commercializes these assets primarily through research collaborations, option-to-license and co-development agreements with large pharmaceutical partners such as Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin and Nippon Shinyaku.
Product overview
MiNA Therapeutics is the global leader in small activating RNA (RNAa) therapeutics, developing a proprietary pipeline of new medicines with an initial focus on genetic medicine. The company's core product portfolio includes MTL-CEBPA (the first RNAa medicine to achieve clinical Proof of Platform, evaluated in over 130 patients), MTL-HBG (an in vivo therapy for sickle cell disease in pre-clinical development), and MTL-STING (a second pipeline candidate for cancer immunotherapy). The RNAa Platform underlies all programs, combining a bioinformatics discovery engine for designing saRNA therapeutics with SMARTICLES liposomal delivery technology. The company collaborates with leading pharmaceutical partners including Lilly, BioMarin, Nippon Shinyaku, AstraZeneca, Boehringer Ingelheim, and Servier to apply its technology platform across therapeutic areas including cancer, metabolic diseases, and rare genetic diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- MTL-CEBPA First-in-class small activating RNA (saRNA) therapeutic designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels. Developed as a combination therapy in cancer, evaluated in over 130 subjects including 80 patients with advanced liver cancer and 50 patients with advanced solid tumor malignancies. The first RNAa medicine to demonstrate clinical Proof of Platform.
- MTL-HBG Investigational in vivo saRNA therapy for Sickle Cell Disease (SCD) and beta-thalassemia. MTL-HBG increases transcription of the HBG gene, enabling patients to produce enhanced levels of fetal hemoglobin (HbF) without the need for preconditioning or complex cell engineering. Delivered using the NOV340 liposomal formulation, with NHP data showing delivery to greater than 60% of committed erythroid progenitors. Currently in pre-clinical development.
- MTL-STING Second drug candidate advanced from MiNA's internal pipeline of saRNA therapeutics. MTL-STING is designed to overcome the downregulation of STING in myeloid cells, a highly validated drug target that plays a key role in immune evasion in cancer.
- RNAa Discovery Platform Proprietary small activating RNA (RNAa) discovery and development platform combining an in-house bioinformatics engine for designing saRNA sequences with the SMARTICLES liposomal delivery technology. Offered to pharmaceutical partners via research collaborations, option-to-license and co-development agreements across oncology, metabolic disease, neurological disorders and rare genetic diseases.
Quantifiable outcome
- MTL-CEBPA demonstrated acceptable safety profile and potential synergistic efficacy in Phase I liver cancer trial with five patients experiencing objective tumour responses including two complete responses.
- +3 more outcomes
Companies that use MiNA Therapeutics
Customer profileSegments4 records
Ideal customer profiles2 records
MiNA Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
MiNA Therapeutics partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Nippon ShinyakucoreResearch collaboration to develop RNAa therapeutics targeting rare neurodegenerative diseases. Collaboration includes licensing agreement option based on early-stage preclinical outcomes.
- BioMarin PharmaceuticalcoreMulti-target research collaboration and option licensing agreement for discovery and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases.
- National University Cancer Institute, Singapore (NCIS)minorInvestigator-sponsored Phase 1 study of MTL-CEBPA in combination with first-line standard of care (atezolizumab and bevacizumab) in patients with previously untreated, advanced hepatocellular carcinoma. F. Hoffmann-La Roche supporting the study.
- Eli Lilly and CompanycoreGlobal research collaboration to develop novel drug candidates using MiNA's proprietary saRNA technology platform. MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly also made a $15m equity investment.
- The Wistar InstituteminorPre-clinical research collaboration combining studies with Wistar Institute on immunological effects of MTL-CEBPA and benefits in combination with other cancer therapies.
- ServiercoreResearch partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
- AstraZenecacoreResearch collaboration to evaluate small activating RNA (saRNA) molecules in metabolic diseases. Combines MiNA's expertise in saRNA discovery with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
- University of LiverpoolminorCollaboration with investigators at the University of Liverpool on the up-regulation of gene targets using saRNA technology.
- Boehringer IngelheimcoreCollaboration and licensing agreement focused on development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's saRNA therapeutics platform.
- Imperial College LondoncoreMulti-year collaborative research agreement to discover and develop new saRNA medicines. MiNA is based at Imperial College London's White City Campus.
- NTNU TrondheimcoreOngoing collaboration with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds. Founder Pål Sætrom is Professor of Bioinformatics at NTNU.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
MiNA Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Alnylam Pharmaceuticals: Global leader in RNA interference (siRNA) therapeutics with multiple approved products. Operates in an adjacent oligonucleotide RNA therapeutic class to MiNA's RNAa platform and is the most established comparable for any RNA-based biotech business model.
- Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with a deep clinical pipeline and multiple approved products. Comparable to MiNA in using synthetic oligonucleotides to modulate gene expression and in the breadth of partnered programs across therapeutic areas.
- Translate Bio (acquired by Sanofi): mRNA therapeutics developer (acquired by Sanofi in 2021) with a comparable RNA-based modality and pipeline spanning rare diseases and vaccines. Useful benchmark for RNA platform M&A valuations.
Direct peers
- Arrowhead Pharmaceuticals: Clinical-stage RNA therapeutics company using siRNA and targeted RNAi delivery platforms. Closely comparable to MiNA in technology modality (oligonucleotide-based gene modulation), business model (broad pharma partnerships), and pipeline breadth across rare and metabolic diseases.
- Dicerna Pharmaceuticals: Oligonucleotide RNAi therapeutic developer (acquired by Novo Nordisk) and co-founded by MiNA co-founder John Rossi. Direct comparable in oligonucleotide modality, GalNAc-delivery approach, and partnership-driven commercialization model.
- Ractigen Therapeutics: China-based clinical-stage developer of small activating RNA (saRNA) therapeutics — the same modality as MiNA. Co-founded by Robert Place (now MiNA's CTO), making Ractigen the most direct small-activating-RNA competitor globally.
- Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company using PRISM platform for stereopure ASOs and siRNAs. Comparable to MiNA in oligonucleotide modality, pipeline targeting rare genetic and neurological diseases, and partnership-heavy development model.
Emerging players
- Stoke Therapeutics: Clinical-stage developer of antisense oligonucleotide therapeutics that upregulate protein expression (TANGO approach). Mechanistically adjacent to MiNA's RNAa platform — both aim to upregulate endogenous gene expression — and Stoke's focus on severe genetic diseases (including a sickle cell/beta-thalassemia program) directly overlaps MiNA's MTL-HBG opportunity.
- ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer platform for ADAR-mediated RNA editing. Adjacent comparator to MiNA as a next-generation RNA therapeutic platform targeting genetic diseases with an oligonucleotide-based approach.
Others
- Vir Biotechnology: Clinical-stage immunology-focused biotech that has explored RNA interference approaches in infectious disease. Comparable in being a private-equity and pharma-partnered biotech business model, though operating in a different therapeutic area.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MiNA Therapeutics social profiles
Digital presenceMiNA Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiNA Therapeutics leadership team
Management profileNumber of profiles
Profiles18 records
MiNA Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiNA Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiNA Therapeutics
What does MiNA Therapeutics do?
MiNA Therapeutics develops a proprietary pipeline of small activating RNA (RNAa) therapeutics — an entirely new class of oligonucleotide medicines that restore or boost normal gene expression at the transcriptional level. Its clinical-stage assets include MTL-CEBPA (cancer immunotherapy combination), MTL-HBG (sickle cell disease) and MTL-STING (cancer immunotherapy), supported by an in-house bioinformatics discovery engine and the in-licensed SMARTICLES liposomal delivery platform. MiNA commercializes these assets primarily through research collaborations, option-to-license and co-development agreements with large pharmaceutical partners such as Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin and Nippon Shinyaku.
Is MiNA Therapeutics a public or private company?
MiNA Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was MiNA Therapeutics founded?
MiNA Therapeutics was founded in 2013. It employs 11 to 50 people.
Where is MiNA Therapeutics based?
MiNA Therapeutics is headquartered in London, United Kingdom, in the Europe region.
How does MiNA Therapeutics make money?
Three revenue lines are on record. Research Collaborations and Licensing is the primary driver. The others are development Milestones and Royalties and equity Investment.
Who are MiNA Therapeutics's main competitors?
Broad incumbents on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Translate Bio (acquired by Sanofi). Direct peers are Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ractigen Therapeutics and Wave Life Sciences. Emerging players are Stoke Therapeutics and ProQR Therapeutics. Vir Biotechnology is listed as an others.
Does MiNA Therapeutics have an API?
No public API is recorded for MiNA Therapeutics.
What industry is MiNA Therapeutics in?
MiNA Therapeutics's product category is RNA-based Therapeutics (saRNA / RNAa). Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.